Observed Signal · Oct 21, 2026 · earnings · Source: SEC API · Impact: 4.5/5
10-Q Financial Filing Analysis for Johnson & Johnson (2026-10-21)
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
This filing reflects critical operational milestone achievements overshadowed by a massive $5.5 billion charge to definitively cap legacy talc ovarian litigation liabilities, while highlighting J&J's pipeline re-acceleration and mid-2027 Orthopaedics spin-off execution.
Track Johnson & Johnson Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
- Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
- Total present value of reserves for talc-related legal matters reached approximately $9.0 billion as of September 27, 2026, while the planned separation of the Orthopaedics business remains on track for mid-2027.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
10-Q Financial Filing Analysis for Lilly (2026-10-29)
Eli Lilly and Company reported strong financial results for the third quarter of 2026, driven by rapid uptake of its incretin portfolio. Total revenue reached $24.40 billion, up 39% year-over-year from $17.60 billion in Q3 2025, underpinned by massive volume expansion for Mounjaro ($10.72 billion, up 65%) and Zepbound ($5.35 billion, up 49%). Incretin medicines represented roughly two-thirds of total revenue for the first nine months of 2026. Consolidated net income for the quarter rose 16% to $6.45 billion ($7.22 diluted EPS), despite absorbing $4.18 billion in acquired in-process research and development (IPR&D) charges from external business development transactions including AtaiBeckley and Curevo. Operating cash flow expanded to $27.42 billion for the first nine months, allowing Lilly to fund aggressive manufacturing expansions ($8.44 billion in CapEx), strategic acquisitions ($10.69 billion net cash paid for acquisitions), and shareholder returns ($4.64 billion in dividends and $4.33 billion in share repurchases). While lower realized prices in the U.S. and China created pricing headwinds, Lilly's manufacturing efficiencies supported an 83.9% gross margin. Management continues to monitor pricing pressures from the Inflation Reduction Act, international reference pricing, and ongoing litigation regarding incretin compounding and patent enforcement.
10-Q Financial Filing Analysis for Medtronic (2026-09-03)
Medtronic plc reported net sales of $9.756 billion for Q1 FY2027 (ended July 31, 2026), marking a 14% year-over-year increase supported by broad segment growth and an additional fiscal week. The company actively expanded its neuroscience portfolio through strategic acquisitions of Scientia Vascular ($681 million) and SPR Therapeutics ($654 million). Additionally, Medtronic advanced the full divestiture of its remaining stake in MiniMed Group following its March 2026 IPO, and executed post-quarter strategic transactions including a $700 million investment in Cornerstone Robotics and a $1.0 billion cross-currency swap. However, the company faces material legal headwinds, actively contesting a $382 million antitrust verdict (subject to trebling) and an $88 million product liability award.
10-Q Financial Filing Analysis for Wiley (2026-09-04)
John Wiley & Sons, Inc. reported its Q1 FY2027 financial results for the three months ended July 31, 2026. Consolidated revenue fell 3% year-over-year to $386.4 million, impacted by lower AI licensing revenue ($13.7 million vs. $28.9 million in the prior-year period) and declines in print book sales, despite a $13.3 million initial contribution from the newly acquired Emerald Publishing. Operating income plunged 91% to $2.9 million, resulting in a net loss of $11.7 million ($(0.23) diluted EPS), compared to net income of $11.7 million in the prior year. Profitability was compressed by $16.5 million in restructuring charges related to its multi-year Global Restructuring Program and $11.0 million in acquisition and integration costs for Emerald Publishing, which was acquired on June 1, 2026, for $462.7 million.
Receive all future signals for Johnson & Johnson & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.